The 2025 ASCO Annual Meeting will take place in Chicago, US, from May 30 to June 3. Duality Bio (9606.HK) will present datafrom two studies evaluating the HER3 ADC candidate DB-1310 and B7H3 ADC candidate DB-1311/BNT324, which is being developed in collaboration with BioNTech SE, in Oral/Rapid Oral presentations. The abstracts will be released on the ASCO website on May 23, 2025 (US local time).

HER3 ADC DB-1310:

•   Title: DB-1310, a HER3-targeted ADC, in pts with advanced solid tumors: Preliminary results from the Ph 1/2a trial

•   Presentation: Oral

• Abstract Number: #3000

• Presentation Date: May 30, 2025 (local time, GMT-5), 14:45-14:57

B7H3 ADC DB-1311/BNT324:

•   Title: DB‑1311/BNT324 (a novel B7H3 ADC) in patients with heavily pretreated castrate-resistant prostate cancer (CRPC)

•  Presentation: Rapid Oral

• Abstract Number: #5015

• Presentation Date: June 1, 2025 (local time, GMT-5), 17:00-17:06